-
Mashup Score: 1
ESMO 2021 patient-reported health-related quality of life (HRQoL) in the context of the ACIS trial, radiographic progression-free survival (rPFS), chemotherapy naïve mCRPC, abiraterone acetate, prednisone, apalutamide.
Source: www.urotoday.comCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 7
ASCO 2021 key subgroups of the ACIS trial, addition of apalutamide + abiraterone acetate + prednisone, ECOG performance status, Patients with mCRPC with ongoing ADT, Fred Saad.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Analysis of two poor prognosis subgroups in #ACIS evaluating apalutamide + abiraterone acetate + prednisone vs PBO + abiraterone acetate + prednisone in #mCRPC. Presented by Fred Saad, MD, FRCS @chumontreal. #ASCO21 written coverage > https://t.co/uA65n15FYs @zklaassen_md @ASCO https://t.co/3gnIcWixMN
-
-
Mashup Score: 0Androgen Annihilation with Abiraterone and Apalutamide in Chemo-Naïve mCRPC - Final Results from ACIS- Dana Rathkopf & Fred Saad - 3 year(s) ago
Metastatic castration-resistant prostate cancer (mCRPC) continues to be driven by androgen signaling, but this patient population has heterogeneous responses to second-generation androgen pathway inhibitors. Apalutamide, an androgen receptor antagonist, and abiraterone acetate, an androgen synthesis inhibitor, have somewhat distinct mechanisms of action and efficacy in the treatment of advanced…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Androgen annihilation with abiraterone and apalutamide in chemo-naïve #mCRPC. @DRathkopf & Fred Saad, MD, FRCS join @CaPsurvivorship to discuss Final results from the #ACIS trial. #WatchNow on UroToday > https://t.co/w0WC4hkNuA @sloan_kettering @chumontreal @NUFeinbergMed https://t.co/iAx22mExT1
-
-
Mashup Score: 2Androgen Annihilation with Abiraterone and Apalutamide in Chemo-Naïve mCRPC - Final Results from ACIS- Dana Rathkopf & Fred Saad - 3 year(s) ago
Metastatic castration-resistant prostate cancer (mCRPC) continues to be driven by androgen signaling, but this patient population has heterogeneous responses to second-generation androgen pathway inhibitors. Apalutamide, an androgen receptor antagonist, and abiraterone acetate, an androgen synthesis inhibitor, have somewhat distinct mechanisms of action and efficacy in the treatment of advanced…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Androgen annihilation with abiraterone and apalutamide in chemo-naïve #mCRPC. @DRathkopf & Fred Saad, MD, FRCS join @CaPsurvivorship to discuss Final results from the #ACIS trial. #WatchNow on UroToday > https://t.co/w0WC4hkNuA @sloan_kettering @chumontreal @NUFeinbergMed https://t.co/w8ML0mEyMn
-
-
Mashup Score: 0Androgen Annihilation with Abiraterone and Apalutamide in Chemo-Naïve mCRPC - Final Results from ACIS- Dana Rathkopf & Fred Saad - 3 year(s) ago
Metastatic castration-resistant prostate cancer (mCRPC) continues to be driven by androgen signaling, but this patient population has heterogeneous responses to second-generation androgen pathway inhibitors. Apalutamide, an androgen receptor antagonist, and abiraterone acetate, an androgen synthesis inhibitor, have somewhat distinct mechanisms of action and efficacy in the treatment of advanced…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Androgen annihilation with abiraterone and apalutamide in chemo-naïve #mCRPC. @DRathkopf & Fred Saad, MD, FRCS join @CaPsurvivorship to discuss Final results from the #ACIS trial. #WatchNow on UroToday > https://t.co/w0WC4hkNuA @sloan_kettering @chumontreal @NUFeinbergMed https://t.co/RfGvYVaxpV
-
-
Mashup Score: 5Androgen Annihilation with Abiraterone and Apalutamide in Chemo-Naïve mCRPC - Final Results from ACIS- Dana Rathkopf & Fred Saad - 3 year(s) ago
Metastatic castration-resistant prostate cancer (mCRPC) continues to be driven by androgen signaling, but this patient population has heterogeneous responses to second-generation androgen pathway inhibitors. Apalutamide, an androgen receptor antagonist, and abiraterone acetate, an androgen synthesis inhibitor, have somewhat distinct mechanisms of action and efficacy in the treatment of advanced…
Source: UroTodayCategories: Latest Headlines, UrologyTweet-
Androgen annihilation with abiraterone and apalutamide in chemo-naïve #mCRPC. @DRathkopf & Fred Saad, MD, FRCS join @CaPsurvivorship to discuss Final results from the #ACIS trial. #WatchNow on UroToday > https://t.co/w0WC4hkNuA @sloan_kettering @chumontreal @NUFeinbergMed https://t.co/eP98bN5Vqb
-
-
Mashup Score: 1
ASCO GU 2021 Genitourinary Cancers Symposium Molecular Correlates of Response to Apalutamide in nmCRPC and Final Results from ACIS, Androgen Annihilation with Abiraterone and Apalutamide in Chemo-Naïve mCRPC, ACIS study prostate cancer, Chemo-Naive Metastatic Castration-Resistant Prostate Cancer
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Molecular correlates of response to apalutamide in #nmCRPC & final results from #ACIS, androgen annihilation with abiraterone and apalutamide in chemo-naïve #mCRPC. Presentation by @AlumkalJoshi @UMRogelCancer. #GU21 written coverage by @aloktewar > https://t.co/CVIa6q7DtR @ASCO https://t.co/6XZ33yasdC
-
-
Mashup Score: 1
ASCO GU 2021 Genitourinary Cancers Symposium, Final Results from ACIS, a Randomized, Placebo-Controlled Double-Blind Phase 3 Study of Apalutamide and Abiraterone Acetate plus Prednisone (AAP) Versus AAP in Patients with Chemo-Naive Metastatic Castration-Resistant Prostate Cancer.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Final results from #ACIS, a randomized, PBO-controlled double-blind p 3 study of apalutamide and abiraterone acetate + prednisone (AAP) versus AAP in pts with chemo-naive #mCRPC. Presented by @DRathkopf @sloan_kettering. #GU21 written coverage > https://t.co/4snKwx5mhW @aloktewar https://t.co/IbtGXF5YOo
-
-
Mashup Score: 1ASCO GU 2021 - 3 year(s) ago
PLEASE NOTE: Materials will be available on a rolling basis as soon as individual embargoes are lifted. Select a product to view View the scientific materials …
Source: www.oncologysciencehub.comCategories: General Medicine News, Latest HeadlinesTweet-
RT @MAWJNJ: #GU21 #prostate day is here and excited about #TITAN #SPARTAN and #ACIS oral presentations today. https://t.co/w59DIp5ZJu Loo…
-
Health-related Quality of Life in #ACIS: a phase 3 trial of apalutamide with abiraterone acetate and prednisone (APA + AAP) vs AAP in #mCRPC. Presentation by @OudardStephane @HopitalPompidou. #ESMO21 written coverage by @WallisCJD @UofT > https://t.co/4seQs7jtPM @myESMO https://t.co/GqhKNSSPNa